<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAW</journal-id>
<journal-id journal-id-type="hwp">sptaw</journal-id>
<journal-title>Therapeutic Advances in Drug Safety</journal-title>
<issn pub-type="ppub">2042-0986</issn>
<issn pub-type="epub">2042-0994</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2042098611429985</article-id>
<article-id pub-id-type="publisher-id">10.1177_2042098611429985</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Does orlistat cause acute kidney injury?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Beyea</surname><given-names>Michael M.</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Garg</surname><given-names>Amit X.</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Weir</surname><given-names>Matthew A.</given-names></name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2042098611429985">Matthew A. Weir, MD ALL-139A, University Hospital, 339 Windermere Road, London, Ontario, Canada N6A 5A5 <email>matthew.weir@lhsc.on.ca</email>.</corresp>
<corresp id="corresp2-2042098611429985">Michael M. Beyea, PhD University of Western Ontario, Kidney Clinical Research Unit, London, Ontario, Canada</corresp>
<corresp id="corresp3-2042098611429985">Amit X. Garg, MD PhD University of Western Ontario, Kidney Clinical Research Unit, Department of Medicine, Division of Nephrology, London, Ontario, Canada Institute for Clinical Evaluative Sciences, Toronto Ontario Canada</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>2</issue>
<fpage>53</fpage>
<lpage>57</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Orlistat is an inhibitor of gastric and pancreatic lipase with proven efficacy in the augmentation and maintenance of weight loss. Although its use has been limited by troublesome but benign gastrointestinal side effects, it has more recently been associated with acute kidney injury (AKI). In this review, we summarize orlistat’s benefits and drawbacks and discuss the body of evidence supporting its role as a cause of AKI. Although we cannot yet draw an unequivocal causal link between orlistat and AKI, there is enough evidence to include orlistat exposure in the clinical assessment of patients with AKI.</p>
</abstract>
<kwd-group>
<kwd>acute kidney injury</kwd>
<kwd>orlistat</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2042098611429985" sec-type="intro">
<title>Introduction</title>
<p>Obesity is fast becoming a worldwide epidemic. Weight management strategies play an important role in mitigating the complications of obesity such as hypertension, dyslipidemia, cardiovascular disease, type II diabetes mellitus and obstructive sleep apnoea [<xref ref-type="bibr" rid="bibr23-2042098611429985">Hubert <italic>et al</italic>. 1983</xref>; <xref ref-type="bibr" rid="bibr28-2042098611429985">Lean <italic>et al</italic>. 1998</xref>; <xref ref-type="bibr" rid="bibr22-2042098611429985">Hu <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr11-2042098611429985">Davy and Hall, 2004</xref>]. Weight reduction achieved through lifestyle and behavioural modifications can be augmented by pharmaceuticals that reduce dietary fat absorption [<xref ref-type="bibr" rid="bibr29-2042098611429985">Li and Cheung, 2011</xref>]. Several of these drugs have proven effective, but their use has been limited by undesirable, but largely benign side effects [<xref ref-type="bibr" rid="bibr29-2042098611429985">Li and Cheung, 2011</xref>]. Orlistat (Roche, Basel Switzerland) is a gastrointestinal lipase inhibitor that is commonly prescribed for weight reduction. Orlistat is currently available in Canada by prescription but is available without a prescription in Australia, the European Union and the United States. Recent studies have suggested an association between orlistat and acute kidney injury (AKI) [<xref ref-type="bibr" rid="bibr8-2042098611429985">Courtney <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr38-2042098611429985">Singh <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr42-2042098611429985">Weir <italic>et al</italic>. 2011</xref>]. In this review we consider the benefits and drawbacks of orlistat and discuss its role as a potential cause of AKI.</p>
</sec>
<sec id="section2-2042098611429985">
<title>Orlistat efficacy</title>
<p>Orlistat, also known as tetrahydrolipstatin is a potent, selective and reversible inhibitor of gastric and pancreatic lipases [<xref ref-type="bibr" rid="bibr16-2042098611429985">Guerciolini, 1997</xref>]. The drug acts primarily by reducing fat absorption from the diet <italic>via</italic> inhibition of triglyceride hydrolysis. Initial human studies demonstrated that orlistat could increase fecal fat excretion by up to 30% [<xref ref-type="bibr" rid="bibr17-2042098611429985">Hauptman <italic>et al</italic>. 1992</xref>].</p>
<p>In the 1990s, several randomized controlled trials (RCTs) examined the efficacy of orlistat on weight reduction and weight loss maintenance. Sjorstrom and colleagues conducted a double-blind placebo-controlled crossover trial that demonstrated that overweight or obese patients achieved a greater reduction in body weight with orlistat (10.2%) compared with placebo (6.1%) after 1 year of treatment combined with a hypocaloric diet [<xref ref-type="bibr" rid="bibr39-2042098611429985">Sjostrom <italic>et al</italic>. 1998</xref>]. Patients were then switched to either orlistat or placebo for a subsequent year and placed on a eucaloric diet. Those who continued orlistat for an additional year regained half as much weight as those switched to placebo. Subsequent RCTs verified the dose–response relationship between orlistat and weight loss in obese patients who were consuming a reduced energy diet [<xref ref-type="bibr" rid="bibr17-2042098611429985">Hauptman <italic>et al</italic>. 1992</xref>; <xref ref-type="bibr" rid="bibr18-2042098611429985">Hill <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr10-2042098611429985">Davidson <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr37-2042098611429985">Rossner <italic>et al</italic>. 2000</xref>]. A meta-analysis of 29 studies of orlistat revealed a mean additional weight loss of 2.89 kg per year of orlistat use compared with placebo [<xref ref-type="bibr" rid="bibr30-2042098611429985">Li <italic>et al</italic>. 2005</xref>].</p>
<p>Secondary benefits of orlistat-induced weight loss have also been evaluated. Benefits such as lower plasma total and low-density lipoprotein (LDL) cholesterol concentrations, smaller waist circumference, lower fasting plasma glucose concentrations, and reductions in systolic and diastolic blood pressure have been found among patients treated with orlistat [<xref ref-type="bibr" rid="bibr18-2042098611429985">Hill <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr10-2042098611429985">Davidson <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr37-2042098611429985">Rossner <italic>et al</italic>. 2000</xref>]. Orlistat use has also been shown to reduce the risk of developing type II diabetes [<xref ref-type="bibr" rid="bibr7-2042098611429985">Colditz <italic>et al</italic>. 1995</xref>; <xref ref-type="bibr" rid="bibr36-2042098611429985">Must <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr22-2042098611429985">Hu <italic>et al</italic>. 2001</xref>]. In a 4-year, double-blind trial of 3305 patients with a body mass index (BMI) over 30 kg/m<sup>2</sup> treated with lifestyle changes, orlistat decreased the risk of new onset type 2 diabetes mellitus by 37% compared with placebo [<xref ref-type="bibr" rid="bibr40-2042098611429985">Torgerson <italic>et al</italic>. 2004</xref>]. Among patients with established diabetes and poor glycemic control, orlistat has been shown to be an effective adjunctive therapy for decreasing fasting plasma glucose concentrations, reducing the percentage of glycated haemoglobin, and decreasing plasma total and LDL cholesterol concentrations [<xref ref-type="bibr" rid="bibr19-2042098611429985">Hollander <italic>et al</italic>. 1998</xref>; <xref ref-type="bibr" rid="bibr34-2042098611429985">Miles <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr26-2042098611429985">Kelley <italic>et al</italic>. 2002</xref>].</p>
</sec>
<sec id="section3-2042098611429985">
<title>Adverse drug events with orlistat</title>
<p>Despite orlistat’s beneficial effects, several drug interactions and adverse drug events have been noted in trials, drug surveillance studies and case reports. Orlistat can reduce bioavailability of fat-soluble drugs, for example amiodarone, cyclosporine, antiepileptic drugs, antipsychotics and thyroxine [<xref ref-type="bibr" rid="bibr15-2042098611429985">Filippatos <italic>et al</italic>. 2008</xref>]. Orlistat’s most frequently observed adverse reactions result from the abundance of undigested fat in the colon, which results in diarrhoea (relative risk [RR] 3.4), flatulence (RR 3.10), bloating, abdominal pain and dyspepsia (RR 1.48) [<xref ref-type="bibr" rid="bibr30-2042098611429985">Li <italic>et al</italic>. 2005</xref>]. Significant reductions in plasma concentrations of fat-soluble vitamins have also been associated with orlistat use although rarely below the lower limit of normal [<xref ref-type="bibr" rid="bibr17-2042098611429985">Hauptman <italic>et al</italic>. 1992</xref>; <xref ref-type="bibr" rid="bibr37-2042098611429985">Rossner <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr40-2042098611429985">Torgerson <italic>et al</italic>. 2004</xref>].</p>
<p>More severe adverse drug events have also been described with orlistat use, including liver injury and AKI. Although data are limited to case reports, between 1999 and 2008 the American Food and Drug Administration received 32 reports of serious liver injury in patients using orlistat [<xref ref-type="bibr" rid="bibr12-2042098611429985">DeLancey, 2011</xref>]. In 2007, Singh and colleagues provided the initial suggestion of orlistat-induced AKI [<xref ref-type="bibr" rid="bibr38-2042098611429985">Singh <italic>et al</italic>. 2007</xref>]. In a patient with underlying stage III chronic kidney disease (CKD; among other comorbidities), initiation of orlistat treatment coincided with an increase in serum creatinine concentration, an increase in urine oxalate concentration and the presence of calcium oxalate crystals in the lumen of the renal tubules. These findings resolved 1 month after discontinuation of orlistat. Courtney and colleagues reported similar findings in a 55-year old woman with diabetic nephropathy [<xref ref-type="bibr" rid="bibr8-2042098611429985">Courtney <italic>et al</italic>. 2007</xref>]. After 5 months of orlistat therapy, the patient’s estimated glomerular filtration rate (eGFR) declined from a baseline of 66 ml/min/1.73 m<sup>2</sup> to 12 ml/min/1.73 m<sup>2</sup> with a documented accumulation of calcium oxalate crystals in the renal parenchyma. In 2007, McLaughlin and Macdougall reported a case series of 33 obese patients with CKD (stages III or IV) taking orlistat for more than 6 months [<xref ref-type="bibr" rid="bibr32-2042098611429985">MacLaughlin and Macdougall, 2007</xref>]. In 6 of the 33 patients (18%), eGFR decreased by &gt;10 ml/min/1.73 m<sup>2</sup> in the 12 months following initiation of orlistat. Following these case reports, a retrospective review of 855 renal biopsies by Karamadoukis and colleagues identified two cases of calcium oxalate crystals in patients with unexplained acute tubular necrosis; both of these patients were taking orlistat at the time of biopsy [<xref ref-type="bibr" rid="bibr24-2042098611429985">Karamadoukis <italic>et al</italic>. 2009</xref>]. These same investigators later identified a 66-year-old man with a history of type 2 diabetes who had been taking orlistat for 3 months. Following hospital admission for AKI, the patient suffered a progressive decline in renal function that eventually necessitated hemodialysis [<xref ref-type="bibr" rid="bibr24-2042098611429985">Karamadoukis <italic>et al</italic>. 2009</xref>]. Most recently, we published a pre–post study using the health administrative databases of Ontario, Canada. We studied 953 patients using orlistat and compared their risk of AKI in the 12 months preceding orlistat initiation to their risk of AKI in the following 12 months [<xref ref-type="bibr" rid="bibr42-2042098611429985">Weir <italic>et al</italic>. 2011</xref>]. This study showed that significantly more patients experienced AKI in the year after orlistat initiation compared with the year prior (18 <italic>versus</italic> 5, <italic>p</italic> = 0.01).</p>
</sec>
<sec id="section4-2042098611429985">
<title>Proposed mechanism of orlistat-associated AKI</title>
<p>Orlistat is thought to cause AKI through enteric hyperoxaluria, which can also be seen in patients with fat-malabsorption syndromes. In this mechanism, unabsorbed fat in the small bowel resulting from orlistat use produces calcium soaps, which reduce the availability of free enteric calcium [<xref ref-type="bibr" rid="bibr2-2042098611429985">Ahmed, 2010</xref>]. As a result, calcium can no longer bind and sequester oxalate inside the gut and this allows increased intestinal oxalate absorption. This leads to increased renal oxalate excretion. Supersaturation of oxalate in renal tubules is a risk factor for calcium oxalate precipitation, which can result in AKI [<xref ref-type="bibr" rid="bibr43-2042098611429985">Williams and Wandzilak, 1989</xref>; <xref ref-type="bibr" rid="bibr20-2042098611429985">Holmes <italic>et al</italic>. 2001</xref>]. This mechanism is supported by the human reports of orlistat-associated AKI and also by the work of Ferraz and colleagues who observed increases in urinary oxalate excretion in rats with orlistat-induced fat malabsorption [<xref ref-type="bibr" rid="bibr14-2042098611429985">Ferraz <italic>et al</italic>. 2004</xref>].</p>
</sec>
<sec id="section5-2042098611429985">
<title>Epidemiology of orlistat-associated AKI</title>
<p>Although the current literature draws associations between orlistat and AKI, it provides little insight into the frequency with which AKI occurs or the factors that may predict it. In our population-based study of 953 patients, we identified 18 individuals (1.9%) admitted to hospital with AKI after they filled prescriptions for orlistat [<xref ref-type="bibr" rid="bibr42-2042098611429985">Weir <italic>et al</italic>. 2011</xref>]. When we consider that 5 individuals (0.5%) had admissions for AKI prior to filling prescriptions for orlistat, this suggests an excess risk of 1.4% over the 1-year follow-up period. However, this estimate is subject to the limitations of our study, most important of which was our inability to identify the aetiology of each patient’s AKI. Even less information is available to identify risk factors for orlistat-associated AKI. Although two out of the three case reports described AKI in patients with pre-existing CKD, CKD is a well-established risk factor for AKI in general, so this observation is unlikely to be specific to orlistat [<xref ref-type="bibr" rid="bibr21-2042098611429985">Hsu <italic>et al</italic>. 2008</xref>]. To assess risk factors for orlistat-associated AKI, we re-examined our data and identified characteristics that differed between those with and without AKI, for which the standardized difference was greater than 10%. Compared with those who did not experience a hospitalization for AKI, patients who did have AKI were slightly older (mean age 60 <italic>versus</italic> 58 years), were generally in poorer health (mean Charlson comorbidity index 2.38 <italic>versus</italic> 1.76, mean number of drugs used in the past year 7.5 <italic>versus</italic> 5.9), and were more likely to have CKD (39% <italic>versus</italic> 10%), hypertension (89% <italic>versus</italic> 77%) and heart failure (39% <italic>versus</italic> 17%). Although this provides an impression of some potentially important risk factors, it is important to note that we assessed a relatively small number of AKI events.</p>
</sec>
<sec id="section6-2042098611429985">
<title>Causality</title>
<p>Despite the associations between orlistat and AKI, establishing causality between drug exposure and adverse outcome is challenging [<xref ref-type="bibr" rid="bibr31-2042098611429985">Macedo <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr33-2042098611429985">Meyboom, 1998</xref>; <xref ref-type="bibr" rid="bibr25-2042098611429985">Karch <italic>et al</italic>. 1976</xref>]. Although innumerable algorithms and probabilistic models have been developed to improve upon the common practice of assigning causality based on expert opinion, no gold standard exists [<xref ref-type="bibr" rid="bibr1-2042098611429985">Agbabiaka <italic>et al</italic>. 2008</xref>]. Therefore, when assessing the relationship between orlistat exposure and AKI, in the absence of a gold-standard methodology, we are left to consider the elements of causal relationships commonly identified in the literature. These elements include an appropriate temporal sequence, a biologically plausible mechanism, the effects of drug challenge, dechallenge and rechallenge, the existence of confirmatory laboratory or pathological data, a consideration of alterative aetiologies and the demonstration of a dose–response relationship [<xref ref-type="bibr" rid="bibr35-2042098611429985">Miremont <italic>et al</italic>. 1994</xref>; <xref ref-type="bibr" rid="bibr3-2042098611429985">Arimone <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr4-2042098611429985">Begaud <italic>et al</italic>. 1985</xref>; <xref ref-type="bibr" rid="bibr13-2042098611429985">Emanueli and Sacchetti, 1980</xref>; <xref ref-type="bibr" rid="bibr27-2042098611429985">Kitaguchi <italic>et al</italic>. 1983</xref>; <xref ref-type="bibr" rid="bibr9-2042098611429985">Danan <italic>et al</italic>. 1993</xref>; <xref ref-type="bibr" rid="bibr5-2042098611429985">Benichou <italic>et al</italic>. 1993</xref>].</p>
<p>In the case of orlistat and AKI, the literature fulfills some but not all of these requirements. Aside from the cross-sectional biopsy study, all studies describe an appropriate temporal relationship between orlistat exposure and AKI outcome. The putative mechanism underlying this relationship is plausible and supported by both animal data and histologic findings in humans. Although there is no documentation of patients being rechallenged with orlistat, the dechallenges reported by the groups of Singh and Courtney showed reversal of the kidney injury. These case reports also provide pathological confirmation of oxalate nephropathy, which is congruent with the proposed pathophysiology.</p>
<p>Although there appears to be strong support for a causal relationship between orlistat and AKI, the body of evidence has some important weaknesses. Case reports offer interesting observations, such as the presence of calcium oxalate crystals on biopsy or the resolution of AKI upon withdrawal of orlistat, but they cannot establish causality nor estimate risk. Observational studies are limited in their ability to establish causality by the influence of bias and confounding variables. The nonrandom allocation of treatment introduces a ‘bias by indication’ where subjects who receive the exposure of interest differ in potentially important ways from those who do not. Confounding variables can also threaten the validity of observational studies, and when these variables are unknown, unmeasured or inaccurately measured, statistical adjustment cannot adequately mitigate their effects. Because these limitations leave the door open for alternative aetiologies of AKI, causality is difficult to establish outside the setting of randomized trials. Unfortunately, trials designed to establish efficacy are not often powered to detect rare outcomes such as AKI [<xref ref-type="bibr" rid="bibr41-2042098611429985">Tsang <italic>et al</italic>. 2009</xref>]. Furthermore, patients with pre-existing CKD, who would likely be at the highest risk for developing AKI, are often excluded from randomized trials [<xref ref-type="bibr" rid="bibr6-2042098611429985">Coca <italic>et al</italic>. 2006</xref>]. The existing trials of orlistat do not provide information on the risk of AKI and given its flagging market share, we are unlikely to see future large-scale trials involving this drug.</p>
</sec>
<sec id="section7-2042098611429985" sec-type="conclusions">
<title>Conclusion</title>
<p>Establishing unequivocal causality in the setting of adverse drug reactions is very difficult. Without evidence from randomized trials or multiple observational studies, we cannot confidently label orlistat a cause of AKI. However, we believe there is sufficient evidence to consider exposure to orlistat a potential cause of AKI. In patients with otherwise unexplained AKI, discontinuation of orlistat would be a reasonable course of action and in patients at risk of AKI, such as those with multiple comorbidities or pre-existing CKD, orlistat should be prescribed with caution and close observation.</p>
</sec>
</body>
<back>
<ack>
<p>Authors acknowledge Brogan Inc. for providing access to the drug identification numbers used to identify eligible drugs.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>The acquisition of new data presented in this review paper was supported by the Institute for Clinical Evaluative Sciences (ICES). ICES is a nonprofit research corporation funded by the Ontario Ministry of Health and Long-Term Care. The opinions, results and conclusions are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred.</p>
</fn>
<fn fn-type="conflict">
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agbabiaka</surname><given-names>T.B.</given-names></name>
<name><surname>Guo</surname><given-names>R.</given-names></name>
<name><surname>Ernst</surname><given-names>E.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis</article-title>. <source>Phytomedicine</source> <volume>15</volume>: <fpage>378</fpage>–<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr2-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Orlistat and calcium oxalate crystalluria: An association that needs consideration</article-title>. <source>Renal Failure</source> <volume>32</volume>: <fpage>1019</fpage>–<lpage>1021</lpage>.</citation>
</ref>
<ref id="bibr3-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arimone</surname><given-names>Y.</given-names></name>
<name><surname>Begaud</surname><given-names>B.</given-names></name>
<name><surname>Miremont-Salame</surname><given-names>G.</given-names></name>
<name><surname>Fourrier-Reglat</surname><given-names>A.</given-names></name>
<name><surname>Moore</surname><given-names>N.</given-names></name>
<name><surname>Molimard</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Agreement of expert judgment in causality assessment of adverse drug reactions</article-title>. <source>Eur J Clin Pharmacol</source> <volume>61</volume>: <fpage>169</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr4-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Begaud</surname><given-names>B.</given-names></name>
<name><surname>Evreux</surname><given-names>J.C.</given-names></name>
<name><surname>Jouglard</surname><given-names>J.</given-names></name>
<name><surname>Lagier</surname><given-names>G.</given-names></name>
</person-group> (<year>1985</year>) <article-title>Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France</article-title>. <source>Therapie</source> <volume>40</volume>: <fpage>111</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr5-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benichou</surname><given-names>C.</given-names></name>
<name><surname>Danan</surname><given-names>G.</given-names></name>
<name><surname>Flahault</surname><given-names>A.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge</article-title>. <source>J Clin Epidemiol</source> <volume>46</volume>: <fpage>1331</fpage>–<lpage>1336</lpage>.</citation>
</ref>
<ref id="bibr6-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coca</surname><given-names>S.G.</given-names></name>
<name><surname>Krumholz</surname><given-names>H.M.</given-names></name>
<name><surname>Garg</surname><given-names>A.X.</given-names></name>
<name><surname>Parikh</surname><given-names>C.R.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease</article-title>. <source>JAMA</source> <volume>296</volume>: <fpage>1377</fpage>–<lpage>1384</lpage>.</citation>
</ref>
<ref id="bibr7-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colditz</surname><given-names>G.A.</given-names></name>
<name><surname>Willett</surname><given-names>W.C.</given-names></name>
<name><surname>Rotnitzky</surname><given-names>A.</given-names></name>
<name><surname>Manson</surname><given-names>J.E.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Weight gain as a risk factor for clinical diabetes mellitus in women</article-title>. <source>Ann Intern Med</source> <volume>122</volume>: <fpage>481</fpage>–<lpage>486</lpage>.</citation>
</ref>
<ref id="bibr8-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Courtney</surname><given-names>A.E.</given-names></name>
<name><surname>O’Rourke</surname><given-names>D.M.</given-names></name>
<name><surname>Maxwell</surname><given-names>A.P.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Rapidly progressive renal failure associated with successful pharmacotherapy for obesity</article-title>. <source>Nephrol Dialysis Transplant</source> <volume>22</volume>: <fpage>621</fpage>–<lpage>623</lpage>.</citation>
</ref>
<ref id="bibr9-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Danan</surname><given-names>G.</given-names></name>
<name><surname>Benichou</surname><given-names>C.</given-names></name>
<name><surname>Flahault</surname><given-names>A.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Score of suspected drug-induced acute liver disorders. Presentation of an evaluation sheet</article-title>. <source>Gastroenterol Clin Biol</source> <volume>17</volume>(<issue>5 Pt 2</issue>): <fpage>H22</fpage>–<lpage>H24</lpage>.</citation>
</ref>
<ref id="bibr10-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davidson</surname><given-names>M.H.</given-names></name>
<name><surname>Hauptman</surname><given-names>J.</given-names></name>
<name><surname>Digirolamo</surname><given-names>M.</given-names></name>
<name><surname>Foreyt</surname><given-names>J.P.</given-names></name>
<name><surname>Halsted</surname><given-names>C.H.</given-names></name>
<name><surname>Heber</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial</article-title>. <source>JAMA</source> <volume>281</volume>: <fpage>235</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr11-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davy</surname><given-names>K.P.</given-names></name>
<name><surname>Hall</surname><given-names>J.E.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Obesity and hypertension: two epidemics or one?</article-title> <source>Am J Physiol</source> <volume>286</volume>: <fpage>R803</fpage>–<lpage>R813</lpage>.</citation>
</ref>
<ref id="bibr12-2042098611429985">
<citation citation-type="gov">
<person-group person-group-type="author">
<name><surname>DeLancey</surname><given-names>S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>FDA issues early communication about ongoing safety review of weight loss drug orlistat</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm180057.htm">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm180057.htm</ext-link></comment> (<day>25</day> <month>June</month> <year>2011</year>).</citation>
</ref>
<ref id="bibr13-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Emanueli</surname><given-names>A.</given-names></name>
<name><surname>Sacchetti</surname><given-names>G.</given-names></name>
</person-group> (<year>1980</year>) <article-title>An algorithm for the classification of untoward events in large scale clinical trials</article-title>. <source>Agents Actions Suppl</source> <volume>7</volume>: <fpage>318</fpage>–<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr14-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferraz</surname><given-names>R.R.</given-names></name>
<name><surname>Tiselius</surname><given-names>H.G.</given-names></name>
<name><surname>Heilberg</surname><given-names>I.P.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion</article-title>. <source>Kidney Int</source> <volume>66</volume>: <fpage>676</fpage>–<lpage>682</lpage>.</citation>
</ref>
<ref id="bibr15-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filippatos</surname><given-names>T.D.</given-names></name>
<name><surname>Derdemezis</surname><given-names>C.S.</given-names></name>
<name><surname>Gazi</surname><given-names>I.F.</given-names></name>
<name><surname>Nakou</surname><given-names>E.S.</given-names></name>
<name><surname>Mikhailidis</surname><given-names>D.P.</given-names></name>
<name><surname>Elisaf</surname><given-names>M.S.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Orlistat-associated adverse effects and drug interactions: a critical review</article-title>. <source>Drug Safety</source> <volume>31</volume>: <fpage>53</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr16-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guerciolini</surname><given-names>R.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Mode of action of orlistat</article-title>. <source>Int J Obesity Relat Metab Disorders</source> <volume>21</volume>(<supplement>Suppl. 3</supplement>): <fpage>S12</fpage>–<lpage>S23</lpage>.</citation>
</ref>
<ref id="bibr17-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hauptman</surname><given-names>J.B.</given-names></name>
<name><surname>Jeunet</surname><given-names>F.S.</given-names></name>
<name><surname>Hartmann</surname><given-names>D.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin)</article-title>. <source>Am J Clin Nutr</source> <volume>55</volume>(<supplement>1 Suppl.</supplement>): <fpage>309S</fpage>–<lpage>313S</lpage>.</citation>
</ref>
<ref id="bibr18-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hill</surname><given-names>J.O.</given-names></name>
<name><surname>Hauptman</surname><given-names>J.</given-names></name>
<name><surname>Anderson</surname><given-names>J.W.</given-names></name>
<name><surname>Fujioka</surname><given-names>K.</given-names></name>
<name><surname>O’Neil</surname><given-names>P.M.</given-names></name>
<name><surname>Smith</surname><given-names>D.K.</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study</article-title>. <source>Am J Clin Nutr</source> <volume>69</volume>: <fpage>1108</fpage>–<lpage>1116</lpage>.</citation>
</ref>
<ref id="bibr19-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hollander</surname><given-names>P.A.</given-names></name>
<name><surname>Elbein</surname><given-names>S.C.</given-names></name>
<name><surname>Hirsch</surname><given-names>I.B.</given-names></name>
<name><surname>Kelley</surname><given-names>D.</given-names></name>
<name><surname>McGill</surname><given-names>J.</given-names></name>
<name><surname>Taylor</surname><given-names>T.</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study</article-title>. <source>Diabetes Care</source> <volume>21</volume>: <fpage>1288</fpage>–<lpage>1294</lpage>.</citation>
</ref>
<ref id="bibr20-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holmes</surname><given-names>R.P.</given-names></name>
<name><surname>Goodman</surname><given-names>H.O.</given-names></name>
<name><surname>Assimos</surname><given-names>D.G.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Contribution of dietary oxalate to urinary oxalate excretion</article-title>. <source>Kidney Int</source> <volume>59</volume>: <fpage>270</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr21-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>C.Y.</given-names></name>
<name><surname>Ordonez</surname><given-names>J.D.</given-names></name>
<name><surname>Chertow</surname><given-names>G.M.</given-names></name>
<name><surname>Fan</surname><given-names>D.</given-names></name>
<name><surname>McCulloch</surname><given-names>C.E.</given-names></name>
<name><surname>Go</surname><given-names>A.S.</given-names></name>
</person-group> (<year>2008</year>) <article-title>The risk of acute renal failure in patients with chronic kidney disease</article-title>. <source>Kidney Int</source> <volume>74</volume>(<issue>1</issue>): <fpage>1</fpage>.</citation>
</ref>
<ref id="bibr22-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname><given-names>F.B.</given-names></name>
<name><surname>Manson</surname><given-names>J.E.</given-names></name>
<name><surname>Stampfer</surname><given-names>M.J.</given-names></name>
<name><surname>Colditz</surname><given-names>G.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Solomon</surname><given-names>C.G.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Diet, lifestyle, and the risk of type 2 diabetes mellitus in women</article-title>. <source>N Engl J Med</source> <volume>345</volume>: <fpage>790</fpage>–<lpage>797</lpage>.</citation>
</ref>
<ref id="bibr23-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hubert</surname><given-names>H.B.</given-names></name>
<name><surname>Feinleib</surname><given-names>M.</given-names></name>
<name><surname>McNamara</surname><given-names>P.M.</given-names></name>
<name><surname>Castelli</surname><given-names>W.P.</given-names></name>
</person-group> (<year>1983</year>) <article-title>Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study</article-title>. <source>Circulation</source> <volume>67</volume>: <fpage>968</fpage>–<lpage>977</lpage>.</citation>
</ref>
<ref id="bibr24-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karamadoukis</surname><given-names>L.</given-names></name>
<name><surname>Shivashankar</surname><given-names>G.H.</given-names></name>
<name><surname>Ludeman</surname><given-names>L.</given-names></name>
<name><surname>Williams</surname><given-names>A.J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>An unusual complication of treatment with orlistat</article-title>. <source>Clin Nephrol</source> <volume>71</volume>: <fpage>430</fpage>–<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr25-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karch</surname><given-names>F.E.</given-names></name>
<name><surname>Smith</surname><given-names>C.L.</given-names></name>
<name><surname>Kerzner</surname><given-names>B.</given-names></name>
<name><surname>Mazzullo</surname><given-names>J.M.</given-names></name>
<name><surname>Weintraub</surname><given-names>M.</given-names></name>
<name><surname>Lasagna</surname><given-names>L.</given-names></name>
</person-group> (<year>1976</year>) <article-title>Adverse drug reactions—a matter of opinion</article-title>. <source>Clin Pharmacol Therapeut</source> <volume>19</volume>: <fpage>489</fpage>–<lpage>492</lpage>.</citation>
</ref>
<ref id="bibr26-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kelley</surname><given-names>D.E.</given-names></name>
<name><surname>Bray</surname><given-names>G.A.</given-names></name>
<name><surname>Pi-Sunyer</surname><given-names>F.X.</given-names></name>
<name><surname>Klein</surname><given-names>S.</given-names></name>
<name><surname>Hill</surname><given-names>J.</given-names></name>
<name><surname>Miles</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial</article-title>. <source>Diabetes Care</source> <volume>25</volume>: <fpage>1033</fpage>–<lpage>1041</lpage>.</citation>
</ref>
<ref id="bibr27-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kitaguchi</surname><given-names>T.</given-names></name>
<name><surname>Nojiri</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>S.</given-names></name>
<name><surname>Fukita</surname><given-names>T.</given-names></name>
<name><surname>Kawana</surname><given-names>T.</given-names></name>
</person-group> (<year>1983</year>) <article-title>Selection of scientific periodicals to monitor drug safety information using Excerpta Medica and Japicdoc in the post marketing surveillance of drugs</article-title>. <source>Drug Informat J</source> <volume>17</volume>: <fpage>177</fpage>–<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr28-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lean</surname><given-names>M.E.</given-names></name>
<name><surname>Han</surname><given-names>T.S.</given-names></name>
<name><surname>Seidell</surname><given-names>J.C.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Impairment of health and quality of life in people with large waist circumference</article-title>. <source>Lancet</source> <volume>351</volume>: <fpage>853</fpage>–<lpage>856</lpage>.</citation>
</ref>
<ref id="bibr29-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>M.F.</given-names></name>
<name><surname>Cheung</surname><given-names>B.M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Rise and fall of anti-obesity drugs</article-title>. <source>World J Diabetes</source> <volume>2</volume>(<issue>2</issue>): <fpage>19</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr30-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Maglione</surname><given-names>M.</given-names></name>
<name><surname>Tu</surname><given-names>W.</given-names></name>
<name><surname>Mojica</surname><given-names>W.</given-names></name>
<name><surname>Arterburn</surname><given-names>D.</given-names></name>
<name><surname>Shugarman</surname><given-names>L.R.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Meta-analysis: pharmacologic treatment of obesity</article-title>. <source>Ann Intern Med</source> <volume>142</volume>: <fpage>532</fpage>–<lpage>546</lpage>.</citation>
</ref>
<ref id="bibr31-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Macedo</surname><given-names>A.F.</given-names></name>
<name><surname>Marques</surname><given-names>F.B.</given-names></name>
<name><surname>Ribeiro</surname><given-names>C.F.</given-names></name>
<name><surname>Teixeira</surname><given-names>F.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability</article-title>. <source>J Clin Pharm Therapeut</source> <volume>28</volume>: <fpage>137</fpage>–<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr32-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacLaughlin</surname><given-names>H.</given-names></name>
<name><surname>Macdougall</surname><given-names>I.C.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Rapidly progressive renal failure associated with successful pharmacotherapy for obesity</article-title>. <source>Nephrol Dialysis Transplant</source> <volume>22</volume>: <fpage>2403</fpage>–<lpage>2405</lpage>; <comment>author reply 2405</comment>.</citation>
</ref>
<ref id="bibr33-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyboom</surname><given-names>R.H.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Causality assessment revisited</article-title>. <source>Pharmacoepidemiol Drug Safety</source> <volume>7</volume>(<supplement>Suppl. 1</supplement>): <fpage>S63</fpage>–<lpage>S65</lpage>.</citation>
</ref>
<ref id="bibr34-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miles</surname><given-names>J.M.</given-names></name>
<name><surname>Leiter</surname><given-names>L.</given-names></name>
<name><surname>Hollander</surname><given-names>P.</given-names></name>
<name><surname>Wadden</surname><given-names>T.</given-names></name>
<name><surname>Anderson</surname><given-names>J.W.</given-names></name>
<name><surname>Doyle</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin</article-title>. <source>Diabetes Care</source> <volume>25</volume>: <fpage>1123</fpage>–<lpage>1128</lpage>.</citation>
</ref>
<ref id="bibr35-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miremont</surname><given-names>G.</given-names></name>
<name><surname>Haramburu</surname><given-names>F.</given-names></name>
<name><surname>Begaud</surname><given-names>B.</given-names></name>
<name><surname>Pere</surname><given-names>J.C.</given-names></name>
<name><surname>Dangoumau</surname><given-names>J.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Adverse drug reactions: physicians’ opinions versus a causality assessment method</article-title>. <source>Eur J Clin Pharmacol</source> <volume>46</volume>: <fpage>285</fpage>–<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr36-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Must</surname><given-names>A.</given-names></name>
<name><surname>Spadano</surname><given-names>J.</given-names></name>
<name><surname>Coakley</surname><given-names>E.H.</given-names></name>
<name><surname>Field</surname><given-names>A.E.</given-names></name>
<name><surname>Colditz</surname><given-names>G.</given-names></name>
<name><surname>Dietz</surname><given-names>W.H.</given-names></name>
</person-group> (<year>1999</year>) <article-title>The disease burden associated with overweight and obesity</article-title>. <source>JAMA</source> <volume>282</volume>: <fpage>1523</fpage>–<lpage>1529</lpage>.</citation>
</ref>
<ref id="bibr37-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossner</surname><given-names>S.</given-names></name>
<name><surname>Sjostrom</surname><given-names>L.</given-names></name>
<name><surname>Noack</surname><given-names>R.</given-names></name>
<name><surname>Meinders</surname><given-names>A.E.</given-names></name>
<name><surname>Noseda</surname><given-names>G.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group</article-title>. <source>Obesity Res</source> <volume>8</volume>: <fpage>49</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr38-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>A.</given-names></name>
<name><surname>Sarkar</surname><given-names>S.R.</given-names></name>
<name><surname>Gaber</surname><given-names>L.W.</given-names></name>
<name><surname>Perazella</surname><given-names>M.A.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor</article-title>. <source>Am J Kidney Dis</source> <volume>49</volume>: <fpage>153</fpage>–<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr39-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sjostrom</surname><given-names>L.</given-names></name>
<name><surname>Rissanen</surname><given-names>A.</given-names></name>
<name><surname>Andersen</surname><given-names>T.</given-names></name>
<name><surname>Boldrin</surname><given-names>M.</given-names></name>
<name><surname>Golay</surname><given-names>A.</given-names></name>
<name><surname>Koppeschaar</surname><given-names>H.P.</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group</article-title>. <source>Lancet</source> <volume>352</volume>: <fpage>167</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr40-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Torgerson</surname><given-names>J.S.</given-names></name>
<name><surname>Hauptman</surname><given-names>J.</given-names></name>
<name><surname>Boldrin</surname><given-names>M.N.</given-names></name>
<name><surname>Sjostrom</surname><given-names>L.</given-names></name>
</person-group> (<year>2004</year>) <article-title>XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients</article-title>. <source>Diabetes Care</source> <volume>27</volume>: <fpage>155</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr41-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsang</surname><given-names>R.</given-names></name>
<name><surname>Colley</surname><given-names>L.</given-names></name>
<name><surname>Lynd</surname><given-names>L.D.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials</article-title>. <source>J Clin Epidemiol</source> <volume>62</volume>: <fpage>609</fpage>–<lpage>616</lpage>.</citation>
</ref>
<ref id="bibr42-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weir</surname><given-names>M.A.</given-names></name>
<name><surname>Beyea</surname><given-names>M.M.</given-names></name>
<name><surname>Gomes</surname><given-names>T.</given-names></name>
<name><surname>Juurlink</surname><given-names>D.N.</given-names></name>
<name><surname>Mamdani</surname><given-names>M.</given-names></name>
<name><surname>Blake</surname><given-names>P.G.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Orlistat and acute kidney injury: an analysis of 953 patients</article-title>. <source>Arch Intern Med</source> <volume>171</volume>: <fpage>703</fpage>–<lpage>704</lpage>.</citation>
</ref>
<ref id="bibr43-2042098611429985">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>H.E.</given-names></name>
<name><surname>Wandzilak</surname><given-names>T.R.</given-names></name>
</person-group> (<year>1989</year>) <article-title>Oxalate synthesis, transport and the hyperoxaluric syndromes</article-title>. <source>J Urology</source> <volume>141</volume>: <fpage>742</fpage>–<lpage>749</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>